Navigation Links
BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
Date:8/15/2013

Fayetteville, Arkansas (PRWEB) August 15, 2013

BiologicsMD, Inc., a privately held drug discovery company developing unique biologic therapeutics for improving bone health, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,450,273, entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone," to The Board of Trustees of the University of Arkansas (U.S.), the Oschner Clinic Foundation (U.S.) and the National University Corporation Kagawa University (Japan). BiologicsMD™ is the exclusive licensee of the patent. The patent claims various forms of composition of matter for the proteins derived by the fusion between collagen-binding polypeptides bound to parathyroid hormone receptor agonists.

BiologicsMD is developing PTH-CBD™ as a novel and unique treatment for osteoporosis and other bone-related disorders. The technology originated in the laboratories of Joshua Sakon, Ph.D. (University Of Arkansas), Robert Gensure, M.D., Ph.D. (previously with the Oschner Clinic and currently with Montefiore Medical Center, NYC) and Osamu Matsushita, Ph.D. (previously with Kagawa University and currently with Okayama University).

"This is the first U.S. patent to issue from a patent family related to PTH-CBD and its use in treating diseases of the bone and other collagen-related disorders," stated J. David Owens, Chief Executive Officer of BiologicsMD. "PTH-CBD has pending methods patent applications in the U.S., along with patents being pursued in major worldwide markets. Because of PTH-CBD’s unique profile of selective targeting and other pharmacologic properties, we foresee a highly differentiated new product to help treat human disease.”

BiologicsMD, Inc. is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive license to develop a new biologic therapeutic, PTH-CBD™, a molecular fusion of PTH (1-33) with the Collagen Binding Domain (CBD) of ColH collagenase. The CBD selectively binds to type I collagen, thus delivering PTH directly to the bone, where it can be most effective in building new bone. This CBD-derived targeting also provides for a long-acting therapeutic, thereby enabling semi-annual dosing for chronic disorders. The company was founded in 2010 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense. BiologicsMD™ is a VIC Technology Venture Development™ portfolio company.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11030677.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Micropharma Limited announces new agreement to commercialize novel natural health products
2. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
3. WuXi PharmaTech Announces Second-Quarter 2013 Results
4. Charm Sciences, Inc. Announces Charm® FAST PHAGE Method Accepted by EPA for Detection of Coliphage in Ground Water
5. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated
6. BCA Announces a New Member Joins Its Blood Center Coperative
7. BioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013
8. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
9. Vivid Learning Systems Announces Newly Designed Industry Websites for MSHA, Electrical Utility Safety, Healthcare and OSHA Compliance
10. Nanounity Announces That the Delmic SECOM Correlative Microscopy System Has Won a 2013 Microscopy Today Innovation Award.
11. Natural Acne Remedy, Probiotic Action, Announces the Unveiling of their New Probiotic Acne Cleanser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for any ... So which eye do you rinse first if a dangerous substance enters both eyes? It’s ... Wash with its unique dual eye piece. , “Whether its dirt and debris, or ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
Breaking Biology News(10 mins):